Kidney cancer is the 7th most common cancer in the UK and its incidence has more than doubled in the past decade.
The researchers hope these new findings will help to identify opportunities for earlier monitoring and intervention in the treatment of kidney cancer.
Many patients with kidney cancer show distinctive genetic damage in their cells. The researchers used sequencing techniques to analyse the genomes of 95 tumours from 33 patients to identify when these major genetic faults occurred.
The genetic changes occur at the chromosomal level with just a single genetic event causing the loss of hundreds of genes in childhood or adolescence.
The researchers found that only a few hundred cells carry these genetic changes and the cells are likely to be common to most of the population.
The cells remain dormant unless further genetic mutations cause them to trigger the disease – only 1-2% of people develop kidney cancer. Further mutations can be caused by smoking, obesity or an inherited risk of kidney cancer.
The new findings, published today in Cell, are part of a trio of papers produced by the TRACERx Renal consortium. It aims to better identify the drivers and differences between kidney cancers to help improve treatment options. TRACERx is made up of researchers and clinicians from the Francis Crick Institute, UCL, Royal Marsden NHS Foundation Trust, and Guy’s and St Thomas’ NHS Foundation Trust.
The two other studies identified three distinct evolutionary paths for kidney cancer. Each type is characterised by the order in which they acquire distinct genetic changes.
These new findings help researchers to understand why patients with similar diagnoses show variations in their prognosis and response to treatments.
The researchers hope their work will lead to better informed treatment plans and more personalised interventions.